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Background: Genome wide association studies (GWAS) are applied to identify genetic loci, which are associated
with complex traits and human diseases. Analogous to the evolution of gene expression analyses, pathway analyses
have emerged as important tools to uncover functional networks of genome-wide association data. Usually,
pathway analyses combine statistical methods with a priori available biological knowledge. To determine significance
thresholds for associated pathways, correction for multiple testing and over-representation permutation testing is
applied.
Results: We systematically investigated the impact of three different permutation test approaches for over-representation
analysis to detect false positive pathway candidates and evaluate them on genome-wide association data of Dilated
Cardiomyopathy (DCM) and Ulcerative Colitis (UC). Our results provide evidence that the gold standard - permuting the
case–control status – effectively improves specificity of GWAS pathway analysis. Although permutation of SNPs does not
maintain linkage disequilibrium (LD), these permutations represent an alternative for GWAS data when case–control
permutations are not possible. Gene permutations, however, did not add significantly to the specificity. Finally, we provide
estimates on the required number of permutations for the investigated approaches.
Conclusions: To discover potential false positive functional pathway candidates and to support the results from
standard statistical tests such as the Hypergeometric test, permutation tests of case control data should be carried out.
The most reasonable alternative was case–control permutation, if this is not possible, SNP permutations may be carried
out. Our study also demonstrates that significance values converge rapidly with an increasing number of permutations.
By applying the described statistical framework we were able to discover axon guidance, focal adhesion and calcium
signaling as important DCM-related pathways and Intestinal immune network for IgA production as most significant
UC pathway.
Keywords: DCM, UC, GWAS, Permutation tests, Pathway analysis* Correspondence: ack@bioinf.uni-sb.de
†Equal contributors
1Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany
Full list of author information is available at the end of the article
© 2014 Backes et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Backes et al. BMC Genomics 2014, 15:622 Page 2 of 15
http://www.biomedcentral.com/1471-2164/15/622Background
Genome wide association studies (GWAS) examine a
substantial set of common genetic variants in larger co-
horts of individuals in order to associate single variants
or sets of variants with biological traits. Hence, GWAS
are usually able to detect significant associations be-
tween single nucleotide polymorphisms (SNPs) and hu-
man diseases. Since the publication of the first GWAS
less than one decade ago in 2005 (e.g. [1] and [2]), far
over 1,000 GWAS have been carried out and published.
The “Catalog of Published Genome-Wide Association
Studies” [3] covers only those GWAS attempting to
assay at least 100,000 SNPs in the initial stage and fur-
thermore considers only SNP-trait associations with p-
values < 1.0 × 10−5. This catalogue lists currently (May,
13th, 2014) 1,920 different papers in PubMed for 1,079
different traits/diseases with 13,380 associations between
variants and the respective traits (for each publication at
most 50 SNPs are considered). Among the most com-
prehensive GWAS considering the screened sample size,
Teslovich and co-workers [4] investigated the genome
for common variants associated with plasma lipids in
more than 100,000 individuals of European ancestry and
reported over 95 significantly associated loci.
The evolution of GWAS analysis can be compared to
the past evolution of expression microarray analysis.
While in first instance the expression of restricted sets
of genes has been analyzed, more substantial sets of gene
expression have been investigated later, and finally, more
sophisticated bioinformatics approaches have been im-
plemented to understand the biological importance and
relevance of the high-throughput gene expression data.
To this end, a large set of gene set enrichment tools and
pathway analysis programs was developed such that
pathway analyses are now a standard for gene expression
studies (no matter whether expression data are ge-
nerated through microarrays or high-throughput tran-
scriptome sequencing). Historically, over-representation
analysis (ORA) was the first method applied, which sta-
tistically evaluates the fraction of genes (e.g. all signifi-
cantly over-expressed genes in a certain disease entity)
in a particular biochemical pathway and compares it to a
background distribution (e.g. all screened genes in the
study that are on the same pathway). Then for each
separate pathway a significance value is calculated based
on common test statistics, e.g., Hypergeometric distri-
bution, binomial distribution or chi-square distribution.
Holmans and co-workers have published a similar ex-
ample of a respective method, however not relying on a
standard distribution [5]. In their ALIGATOR approach
significant SNPs are mapped to significantly associated
genes, each gene is however counted only once regard-
less of the total number of significantly associated SNPs.
To calculate significance values SNPs were drawnrandomly from all SNPs such that the genes containing
this SNP were added to the list of significant genes.
Overall, 5,000 random gene lists were generated and em-
pirical p-values were calculated for all GO categories
with more than 2 significant genes. Following these
over-representation methods, Functional Class Scoring
(FCS) approaches were developed by the scientific com-
munity [6], where first a gene-level statistic is calculated
(e.g. relying on ANOVA, Q-statistic, signal-to-noise ra-
tio, t-test, WMW-test or Z-scores). Next, the gene-level
statistics is aggregated into a pathway level statistics.
Here, one of the most commonly applied approaches is
the Gene Set Enrichment Analysis [7] (GSEA), which re-
lies on a Kolmogorov-Smirnov-like test statistic. To de-
termine the significance level either a self-contained null
hypothesis can be applied where class labels are per-
muted, or a competitive null hypothesis can be applied
where gene labels for each pathway are permuted, and
the set of genes in the pathway is compared to a set of
genes that are not in the pathway. While usually signifi-
cance scores have to be calculated by permutation tests,
at least in the case of an unweighted gene set enrich-
ment analysis, an exact calculation using dynamic pro-
gramming has been developed [8]. GSEA approaches
that originally were applied in gene expression studies
have already been successfully adapted to GWAS [9]. To
carry out over-representation analysis (ORA) and FCS
approaches a manifold of different stand-alone as well as
online tools has been developed over the past decades.
A review by Huang and co-workers lists as much as 68
different computational tools that were developed until
2008 [10].
Notably, ORA as well as FCS in their basic implemen-
tations do not consider pathway topologies but only sets
of genes. Here, genes that are on different parts of the
network have the same meaning as genes that are dir-
ectly influencing each other. Since the direct relation
and interaction of genes can potentially add value to the
gene set analysis, a third generation of bioinformatics
tools has been implemented, covering the topology of
pathways. One class of tools combined classical algo-
rithms such as GSEA with pathway topology as imple-
mented in the FIDEPA algorithm [11]. Other examples
of pathway topology based algorithms include impact
factor based methods [12], NetGSA [13], ScorePAGE
[14]. Recently, we published an integer linear program-
ming approach for detecting significantly dysregulated
pathways in gene expression data [15,16].
While gene set and pathway analyses have become a
standard for gene expression profiling, only a fraction of
published GWAS studies made use of such analyses.
There is a particular challenge as described by Khatri
et al. [6], namely low resolution biological resources.
While GWAS data comprises the different genotypes for
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KEGG [17], MetaCyc [18] or Reactome [19]) specify
which genes are actively involved in a particular path-
way. Thus, first a SNP to gene and then a gene to path-
way mapping has to be carried out. To this end, several
approaches exist, for example, in the case of the “Path-
ways of Distinction Analysis” (PoDA, [20]) just the most
significant SNP is considered for each gene in order to
get a single reference per gene. This however means that
the respective SNP is not necessarily significantly associ-
ated with the considered disease. Besides comprehensive
scoring approaches such as SPOT [21], another straight-
forward approach treats genes as significant where at
least one significant SNP has been detected. A compre-
hensive comparison of several algorithms for pathway
analysis using Crohn’s Disease is presented in [22].
Liu et al. evaluate ORA and GSEA approaches for
Alzheimer Disease [23]. Additional approaches are listed
in the review by Wang et al. [24].
Additionally, although cohort sizes of GWAS studies
are very large and frequently thousands of patients are
screened, no SNP may pass genome wide significance
after adjustment. This may be due to the fact that the
considered trait actually does not depend on genetics in
the respective study or that the effect sizes are too small.
Here, pathway analysis can contribute to improve the
power, while the single genes are not significant the
overall pathway might be significant.
For all approaches it is essential to identify real associ-
ations and reject as many false positive results as pos-
sible. In the present study, we systematically explore the
effect of different permutation tests in two sets of
GWAS data. The most common approach is permuting
the case–control status (column permutations). How-
ever, frequently raw data are not available but rather ag-
gregated SNP information. In addition, for web-based
applications, uploading of raw data that are required for
permuting case–control status can be too time-
consuming. Thus, we also evaluated strategies that do
not require the case–control status, including permuting
significance values of the original case–control status
(row permutation I) and randomly permuting the gene
labels instead of the significance values of SNPs (row
permutation II). In the latter case, the LD is maintained
and the sizes of random gene sets correspond to the ori-
ginal size of gene sets. Beyond testing the different per-
mutation test strategies, we assess the required number
of permutations to reach statistically stable results. The
pathway computations were conducted exemplary on
two GWAS datasets for Dilated Cardiomyopathy (DCM)
and for Ulcerative Colitis (UC) using the public gene set
analysis toolkit GeneTrail [25,26]. Our study addresses
the questions, which permutation strategy should be ap-
plied to GWAS data and how many permutations arerequired in order to reach reliable results. In addition,
our combined analysis strategy provides novel insights
into the molecular pathways involved in DCM.
Results
Influence of permutation tests on the number of
significant genes
First, we evaluated how different permutation tests influ-
ence the number of significant genes. As lead application
we employed our method to a GWAS dataset of 909 pa-
tients suffering from Dilated Cardiomyopathies (DCM)
and 2,120 population-based controls. As first analytical
step, we matched all SNPs to the respective genes ac-
cording to the information provided by the manufac-
turer. When one SNP mapped to multiple genes, all
genes were taken into account. Next, genes were consid-
ered as significant, if at least a single SNP was discov-
ered in that gene (significance value of p < 0.05, adjusted
for GC and covariates). The SNPs were not adjusted for
multiple testing since a standard Bonferroni correction
did not yield any individual genome-wide significant
SNPs in this study. For the original data set we calcu-
lated 6,226 significantly associated genes. By carrying
out 20,000 permutation runs across the columns of the
GWAS matrix, corresponding to permutation of case–
control status, we found a significantly decreased (z-
score based p-value <10−4) number of genes in the range
of 5,500 genes per permutation test, as indicated by the
red distribution in the Histogram plot (Figure 1). We
likewise carried out 20,000 permutations across the rows
of the GWAS matrix, corresponding to randomly per-
muting the significance values per SNP. Hereby we cal-
culated a significantly increased (z-score based p-value
of <10−4) number of significantly associated genes
(around 8,000 per permutation test run), as demon-
strated by the green distribution in Figure 1. Altogether,
both distributions were significantly different from each
other (two-tailed unpaired t-test of <10−10). In the third
permutation test strategy, i.e. permuting the genes, the
number of significant genes was preserved. The sub-
stantial difference between the three analyses is well
explained by the completely different permutation ap-
proaches. While e.g. for the column permutations corre-
lations between SNPs are obtained, this information is
completely lost in the case of permuting SNPs. This fact
is of particular importance when hypotheses are tested
that combine information across SNPs.
Moreover, we also evaluated the influence of the alpha
level on the number of significant SNPs and decreased
the threshold to 0.01, 0.001, 0.0001 and 0.0001, respect-
ively. In this analysis, we found a rapidly decreasing
number of significant genes although we define a gene
as significant if it contains just a single significant SNP.
Specifically, the number of genes decreased to 39.7%,
Figure 1 The two distributions represent the result of the
column and row I permutation test approach. The original data
set revealed a total of 6,226 significantly associated genes (dashed
line). Following permutations of the case–control status (red), a
significantly decreased number of genes is discovered to be
significant. Following the SNP permutations (row permutations I), a
significantly increased number of genes was discovered to be
significant. The second row based permutation strategy preserved
the number of genes (6,226). The respective gene sets have been
used as input for the pathway analysis.
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the lowest threshold of 0.0001.
Influence of permutation tests on pathway analysis
Next, we explored the influence of the different permu-
tation strategies for GWAS pathway analyses relying on
the Hypergeometric distribution. By using GeneTrail, we
investigated 241 different biochemical pathways from
the KEGG database and studied whether more or less
genes than expected by chance are located on each path-
way. The respective pathways are then denominated as
enriched or depleted, respectively. While the depleted
pathways contain the genes that are not affected by the
disease, the enriched pathways are significantly altered.
Therefore, here we focus on enriched pathways and pro-
vide the depleted pathways for completeness.
Analogously to the single gene analysis, we evaluated
the influence of the alpha level on the pathway analysis
to calculate significant SNPs by decreasing the threshold
from 0.05 to 0.01, 0.001, 0.0001 and 0.0001, respectively.
Please note that only the significance level for identifica-
tion of SNPs has been varied, while the threshold to dis-
cover significant pathways was in all analyses 0.05
following adjustment for multiple testing. For the ori-
ginal alpha level of 0.05 (gene set size: 6,226), we calcu-
lated 54 significant pathways after adjusting for multiple
testing. By considering SNPs with significance below
0.01 (gene set size: 2,470), just 11 enriched pathwaysremained. When increasing the stringency of the thresh-
old to 0.001 (gene set size: 466), no significant pathway
remained. These results suggest that 0.05 or 0.01 are
reasonable thresholds. The results in the manuscript are
based on the least stringent alpha level of 0.05.
For each pathway, we calculated four different signifi-
cance values. Two significance values correspond to the
two distributions described above and outlined in
Figure 1 (column permutations, row permutations I). The
third p-value corresponds to the permutation of genes
(row permutation II) and the fourth p-value corresponds
to the original data, respectively. In the latter case, signifi-
cance values were computed using the Hypergeometric
distribution and significance values were adjusted for mul-
tiple testing using the Benjamini Hochberg approach [27].
For the permutation tests, we calculated a significance
score for each pathway p as the fraction of all 20,000
column and row permutation tests with higher signifi-
cance for pathway p as the original data set. The signifi-
cance values resulting from the four sets of pathway
analysis are presented as bar chart in Additional file 1:
Figure S1. While column permutation tests (average
p-value of 0.33) and row permutation tests I (average
p-value of 0.36) were clearly less significant than the ori-
ginal results (average p-value of 0.24), the second row
permutation test strategy showed substantially smaller
p-values (average p-value of 0.07). As two-tailed paired
t-tests indicate, the difference between original p-values
and row permutations I was higher (2*10−13) than the
dissimilarity between original p-values and column
permutations (2*10−10). The highest difference was
however calculated for row permutations II with a
p-value of < 10−16. Although row I and column permu-
tation tests showed a slightly higher concordance to
each other, the difference between both approaches was
still significant (5*10−7). All significance values for all
pathways and all permutation tests are provided in
Additional file 2: Table S1.
The original motivation for permutation tests is to
cross-check the p-values obtained by classical tests such
as the Hypergeometric distribution to discover putative
false positive pathways. Based on the results above, we
conclude that column permutation as well as row I per-
mutation tests highlight relevant pathways. In contrast,
row permutation tests II in all cases confirmed the re-
sults of the Hypergeometric test, even with substantially
lower significance values, not adding to the specificity of
the pathway analysis.
Consequently, we focus in the following on the inter-
pretation of column permutation tests and row permuta-
tion tests I. To understand the differences between the
Hypergeometric test and the two remaining permutation
tests, we calculated the overlap in significant pathways.
As presented in the area proportional Venn diagram in
Backes et al. BMC Genomics 2014, 15:622 Page 5 of 15
http://www.biomedcentral.com/1471-2164/15/622Figure 2, 79 distinct KEGG pathways were significant in
at least one of the three tests. The highest number of
significant pathways was discovered for the original data
(54), while permutation testing for columns and rows re-
vealed 41 and 45 significant pathways, respectively. Re-
markably, the overlap between all three tests was
substantial, with 20 pathways remaining significant in all
three tested scenarios. The most significant of these
pathways included “axon guidance”, “calcium signaling”
and “focal adhesion”. All 20 pathways that remained sig-
nificant in the three analyses are shown in Figure 3.
Here, the distance from the center reflects each path-
way’s significance, where larger distances correspond to
increased significance. All pathways outside of the area
represented in the center of Figure 3 are significant at a
threshold of p = 0.05. As this figure shows, the concord-
ance between permutation of rows and columns appears
generally high, at least for the subset of 20 pathways, as
demonstrated by a correlation of 0.84. As mentioned
above, some pathways were highly significant (p-value
<0.005). Notably, the three most significant pathways
with respect to the original distribution belonged to the
20 pathways being significant in all three tests such that
row- as well as column permutations confirmed the ori-
ginal results. These networks contain “axon guidance”,
“calcium signaling pathway” and “focal adhesion” with
adjusted p-values of below 10−5 (original set). As de-
tailed in the discussion section, all three pathways are
important key networks for cardiovascular disorders. Be-
sides these, further 26 pathways have been excluded by
both approaches, being significant just in the original
data set results (Additional file 3: Figure S2).
Again, column and row permutation tests I showed a
generally good concordance in marking potentiallyFigure 2 Venn diagram showing the overlap between the three differinteresting candidate pathways such as “vascular smooth
muscle contraction” or “dilated cardiomyopathy” as likely
false positives. Notably, for these pathways the second row
permutation test strategy found the pathways as highly
significant. In case of “dilated cardiomyopathy” the ori-
ginal p-value was 0.02 while row permutations II reveal a
p-value of 0.0003. For “vascular smooth muscle contrac-
tion” the original p-value was 0.01 and for row permuta-
tions II as low as 10−4. A potential reason is a size bias
since the genes included in both networks are substan-
tially longer compared to the average length of human
genes (p-values according to Wilcoxon Mann–Whitney
test of 2*10−8 and 2*10−6, respectively), demonstrating that
the applied column and row I based permutation ap-
proaches effectively handles this size bias while the second
row based permutation strategy does not.
Our analyses suggest that row I and column permuta-
tions provide fully concordant results and that one of the
two approaches will be sufficient. Nevertheless, while for
the total set of networks included in the Venn diagram in
Figure 2 (all pathways that are significant at least in a single
test) in 31 cases row and column permutation tests were
concordant according to an alpha level of 0.05 and fur-
ther 26 pathways were rejected by both strategies, in as
much as 22 cases discordance between row I and col-
umn permutation tests was observed. Specifically, in 5
cases only the original analysis and column permuta-
tions were significant. In 3 cases only the original ana-
lysis and row permutations were significant (details are
provided in Figure 3B); in 5 and 9 cases, only row per-
mutations or respective column permutations were sig-
nificant. Notably, in as many as 11 cases significant
results in row and column permutations were discov-
ered while original results did not show any significanceent approaches.
Figure 3 Overview on the 20 significant pathways across all
approaches (Figure 3A), in both permutation tests (Figure 3B)
and just in original calculations (Figure 3C). The figure presents the
significance values for the 20 pathways (ordered clockwise according
to decreasing significance as calculated by the Hypergeometric
test), showing p-values < 0.05 for all three approaches. The further
away from the middle the higher the significance scores (on a
logarithmic scale). The grey shaded area in the middle corresponds
to non-significant pathways. Significance values have been cut
at 10−5.
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substantial fraction of these 11 paths still exhibited low
p-values, e.g. “Osteoclast differentiation” and the “T cell
receptor signaling pathway” slightly missing the alpha
level in the original analysis with p-values of 0.051 and0.057. A total of 7 pathways revealed Hypergeometric
test p-values below 0.1 (see Additional file 2: Table S1).
Since row I and column permutation results do not
agree in all cases, a detailed consideration of the results
is required. An example where row permutation tests
yielded a significant enrichment while column permu-
tations revealed a higher and non-significant value in-
cludes the “long term potentiation”, as presented in
Figure 4 (panels A and C). Vice versa, panels B and D
of that figure visualize an example where column
permutations provided a significant result while row
permutations were not significant (hypertrophic
cardiomyopathy, HCM). In both cases, large parts of
genes participating in the pathways are significant
in the GWAS, highlighted in red in the representations
on the lower part of Figure 4. Additional 11 pathways
where the Hypergeometric tests did not yield
any significant result, but permutation tests did, in-
clude Thiamine, Phenylalanine metabolism, Shigellosis,
Hematopoietic cell lineage, Taste transduction, Pancre-
atic cancer, Ubiquinone and other terpenoid-quinone
biosynthesis, T cell receptor signaling, Osteoclast differ-
entiation, Leishmaniasis and Amino sugar and nucleo-
tide sugar metabolism. These pathways are however
only loosely connected to DCM.
Our analyses considered significantly enriched as well
as depleted pathways, representing both tails of the dis-
tribution of all permutation tests. In many cases it makes
sense to treat enriched and depleted pathways separately
from each other, corresponding to a one-tailed analysis.
While the enriched pathways are most affected by the
disease, depleted pathways may provide information on
molecular networks that are not affected by the trait of
interest. We thus calculated for each of the 241 path-
ways how many percent of the row and column permu-
tation tests are enriched and depleted. As shown in
Figure 5, row and column permutation tests revealed on
average a good correlation as indicated by the R2 value
of 0.87. Here, the significantly enriched and depleted
pathways are highlighted in green and red. Notably,
many pathways are enriched or depleted in almost all
permutation test runs including 32 pathways that are
100% enriched and located in the upper right corner
in Figure 5, and 8 pathways that are 100% depleted
and located in the lower left corner of this figure. The
pathways in the upper right corner also contain the
three previously described pathways “axon guidance”,
“calcium signaling pathway” and “focal adhesion”. Re-
markably, four pathways are clear outliers in Figure 5
(upper middle part of the diagram), containing “Cya-
noamino acid metabolism”, “fatty acid biosynthesis”,
“vitamin B6 metabolism” and “butirosin and neomycin
biosynthesis”. These are likely false positives due to a
limited number of SNPs in the genes of the respective
Figure 4 Difference between row- and column permutations. The histograms in panel A and B show for two pathways the significance
values as calculated for row and column permutations, respectively. Panels C and D present the respective pathways as provided by KEGG. Here,
red marked genes correspond to significant genes in our GWAS.
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pathway. To effectively adjust for such artifacts, the
analysis could be restricted on larger pathways, how-
ever, leading to a loss of information on smaller paths.
All significance values for enriched and depleted path-
ways are provided in Additional file 4: Table S3.
Required number of permutation tests
Another important question in GWAS pathway analysis
is how many permutations have to be carried out in
order to obtain stable results with respect to the consid-
ered pathways? Here, one common choice is to generate
1,000 different permutations, just a small fraction of the
exponentially growing permutation number. We ex-
plored the Coefficient of Variation (CV), the ratio of the
standard deviation to the mean as potential criterion for
estimating the required number of permutations. In de-
tail, we started by sampling 100 of the 20,000 permuta-
tion tests and stepwise increased the number. For each
permutation set size 1,000 random drawings were car-
ried out to calculate average value, standard deviation
and CV value for column as well as row permutations.First, we considered the average and standard deviation
for all pathways with 1,000, 2,000 and 5,000 permutation
tests for row and column permutations separately.
Additional file 5: Figure S3 shows exemplarily the de-
pendency between column permutation test number and
CV. Particularly for the significant pathways on the left
of the vertical black line (p = 0.05), the difference be-
tween 2,000 permutations (blue) and 5,000 permutations
(green) was not significantly larger than between 1,000
and 2,000 permutations. To exactly assess at which
number of permutations the significance values converge
for a certain pathway, we estimated the influence of the
number of column and row permutations on the signifi-
cance for “pathways in cancer”. Figure 6 presents the
average significance score and the respective standard
deviation for up to 15,000 of these permutations in the
upper panel. In the lower panel of that figure the coeffi-
cient of variation for both, column and row permuta-
tions, is presented. Here, it can be seen that significance
values converge rapidly, resulting in our example in a
moderate coefficient of variation, such that in our case
indeed 2,000 permutations were sufficient to estimate
Figure 5 Comparison between enriched and depleted pathways. Each dot corresponds to one pathway. Red dots correspond to depleted
and green dots to enriched pathways.
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dence interval and coefficients of variation of approxi-
mately 0.1.
Ulcerative Colitis (UC) pathways
To validate our approach, we evaluated GWAS data
measured from Ulcerative Colitis (UC) patients. Analo-
gous to our results in the previous chapters, we focused
on the most complex permutation test approach and
carried out 10,000 permutations of the case–control sta-
tus permutations. Following our original analysis strat-
egy, we selected an alpha level of 0.05 to consider a SNP
as significant. For the original data set we calculated
7,082 significant genes. In line with the results for DCM,
we also found a significantly decreased number of genes
in the permutation tests with an average of 6,775 genes.
In the enrichment analysis we discovered as much as
51 KEGG pathways to be significant following adjust-
ment for multiple testing at an alpha level of 0.05. In the
subsequent evaluation of the permutation tests, 30 of
these pathways (59%) were marked as potentially false
positive paths and 21 remained significant. The two
most significant networks with p-values of 6*10−4 and
8*10−4, respectively were “Intestinal immune network
for IgA production” and “Toxoplasmosis”. The nextpathways with significance values of 0.001, 0.002 and
0.003 contain “Maturity onset diabetes of the young”,
“Fat digestion and absorption” and “Glycerophospholipid
metabolism”. The first pathway that has been excluded
by the permutation tests was “Cell adhesion molecules”.
All significance values are provided in Additional file 6:
Table S2.
Next, we evaluated the required number of permuta-
tions for the UC data set with the same approach as for
DCM. Corresponding to our previous results on DCM,
we again did not discover substantial differences for the
relevant pathways (p = 0.05). The difference between
2,000 permutations (blue) and 5,000 permutations
(green) was not significantly larger than between 1,000
and 2,000 permutations (Additional file 7: Figure S4).
Since this analysis revealed that for very significant path-
ways very small permutation test numbers suffice, we
again picked a pathway with a p-value in the range of
0.05 in order to estimate the finally required number of
permutations. As an example, we investigated the path-
way “RNA polymerase”. As was observed in the case of
DCM, the significance values rapidly converged for this
pathway. Additional file 8: Figure S5 demonstrates that,
again, significance values rapidly converge with increas-
ing permutation test number and that for permutation
Figure 6 Influence of the number of permutations. The upper panel of the figure shows for column (red) and row (green) permutation tests
the average significance value and the standard deviation for “Pathways in cancer”. The lower panel shows the coefficient of variation (CV) for
both approaches.
Backes et al. BMC Genomics 2014, 15:622 Page 9 of 15
http://www.biomedcentral.com/1471-2164/15/622test numbers between 1,000 and 2,000 coefficients of
variation below 10% can be obtained. Generally, the re-
sults calculated for UC matched well to the results ob-
tained for DCM.
Comparison of DCM and UC
Finally, we investigated on the overlap of DCM and UC
genes and pathways. Of the 7,082 genes calculated for
UC, 3,919 (55%) were likewise detected for DCM,
representing a substantial overlap. Considering the
pathways that are significant according to the Hyper-
geometric distribution, still 24 of the 51 UC pathways
are overlapping with DCM (47%). After applying the
permutation tests, however just 2 of the 21 pathways
are overlapping between both diseases (10%). The re-
spective pathways are “GnRH signaling pathway” as
well as “Toxoplasmosis”. This analysis indicates that
the permutation tests filter out a substantial part of
false positive pathway candidates.Discussion
Pathway analysis for GWAS has already been applied to
various diseases such as pancreatic cancer [28], type 2
diabetes [29], Alzheimer [23], non-syndromic cleft lip
[30] and many others. In our study we explored pathways
in a GWAS of dilated cardiomyopathy and at the same
time systematically evaluated different permutation test
strategies. While we obtain reliable results using a gene-
set based approach, relying on an over-representation sta-
tistics which is calculated via the Hypergeometric test,
topology based methods such as scorePAGE [14] or
optimization based algorithms [15,16] should be consid-
ered to improve the signal to noise ratio in GWAS and
enhance the systems understanding of human pathogenic
processes. Yet, there remain several challenges in GWAS
pathway analysis:
The first challenge is that existing pathway resources
such as KEGG having a lower resolution and comprising
relatively few genes compared to genome-wide SNP
Backes et al. BMC Genomics 2014, 15:622 Page 10 of 15
http://www.biomedcentral.com/1471-2164/15/622datasets. Additionally, GWAS consider multiple variants
in each single gene and even more variants in non-
coding regions. Thus, associated variants first have to be
assigned to genes and significance scores per gene have
to be calculated. Here, various algorithms such as SPOT
[21] have been developed. Straightforward approaches
treat genes as significant where at least x significant
SNPs have been detected in that gene. This however
may introduce a bias towards longer genes, as we dem-
onstrate in our study. Here, the permutation tests of
rows and columns were very effective to account for po-
tential size bias. Other approaches that could be applied
in order to take gene size into account are to normalize
the number of significant variants per gene by the gene
length or by the total number of variants on this gene in-
cluded in the study. We explored the respective ap-
proaches but did not discover improved results compared
to the straightforward method employed in our study.
Another challenge is significance value calculation of
permutation tests and permutation test numbers to be
carried out. Generally, the significance score for permu-
tation tests is calculated as fraction of all permutations
with more significant result than in the original analysis.
To avoid p-values of zero, the minimal significance score
to be reached by this method is 1/(# of permutations).
One approach to account for this is to calculate p-values
based on tail approximation. Knijnenburg and co-
workers [31] present an algorithm where the tail of the
distribution of permutation values is approximated by a
generalized Pareto distribution, which accurately esti-
mated significance values. Reducing the number of per-
mutations is of special importance when considering
many different biological categories. For our approach
few thousand permutations were sufficient in order to
gain valuable insights into the molecular pathogenesis of
DCM. For our ORA based approach it was however es-
sential to permute the case–control status as well as the
significance values of single SNPs. A similar claim has
already been made by Efron and Thibsirani [32] who ad-
dress the problem of identifying differentially expressed
groups of genes from a microarray experiment based on
the gene set enrichment analysis (GSEA).
Despite these challenges, pathway analysis helps to
understand pathogenic processes on a molecular level.
By applying the ORA based pathway analysis for DCM
we detected association signals to be enriched in differ-
ent pathways indicating their modulation by common
variants. Most importantly, three very highly significant
pathways (adjusted original p-values below 10−5) that
remained significant after column and row permutation
tests were discovered, including “axon guidance”, “calcium
signaling pathway” and “focal adhesion”. The “focal adhe-
sion pathway” for instance is an interacting network of
proteins that is essential for maintaining cardiomyocyteintegrity [33], mechanosensing, and mechanotransduction
[34-36]. Perturbations in this pathway have been observed
following chronic alterations in cardiac afterload and
maladaptive remodeling [37], all important in the
pathogenesis of DCM. While calcium signaling is very
obvious to be important for DCM - a disease with the
hallmark of disturbed calcium homeostasis - axon
guidance, which was most substantially enriched, rep-
resents a more surprising finding. It may indicate a
possible link between DCM and abnormalities in car-
diac innervation. For instance, chronic heart failure
and its progression are associated with increased sym-
pathetic tone, decreased vagal control, and regional
variability in innervation [38,39]. The components of the
axon guidance pathway are also involved in cardiac devel-
opment and differentiation [40,41]. Moreover, the main-
tenance of a normal cardiac function depends on the
autonomic nervous system, characterized by an intricate
balance between the sympathetic and parasympathetic ac-
tivity. Not only do they regulate the cardiac conduction
system, but also orchestrate heart rate and force of con-
traction. In congenital heart diseases as well as cardiac is-
chemia and heart failure, we can find altered cardiac
innervation, with their underlying developmental and
regulatory mechanisms. Vascular sympathetic innervation
is an important determinant of blood pressure and blood
flow, with recent data suggesting that vascular endothelial
cells (EC) express semaphorin 3A (SEMA3A), a repulsive
axon guidance cue. As such, Damon et al. have looked
closely at rat aortic vascular ECs expressing SEMA3A as
well as other class 3 semaphorins and found out that vas-
cular EC-derived SEMA3S inhibited sympathetic axon
growth [42]. Moreover, Fish et al. looked at the interaction
of members of the Slit family of secreted ligands with
Roundabout (Robo) receptors, which provide guidance
cues for many cell types. The Slit-Robo signaling pathway
is involved in the development of the pericardium, the
sinus horn myocardium, and the alignment of the caval
veins. In zebrafish, miR-218 and multiple Slit/Robo signal-
ing components are required for heart tube formation [40].
Mommersteeg et al. uncovered that reduced Slit3 binding
in the absence of Robo1 led to an impaired cardiac neural
crest survival, adhesion, and migration, with pericardial de-
fects created by abnormal localization of the caval veins
combined with ectopic pericardial cavity formation [43]. In
diseased hearts, nonuniform innervation promotes en-
hanced sympathetic activity and therefore life-threatening
arrhythmias. Miwa and collaborators demonstrated that
GDNF promotes sympathetic innervation in both native
cardiac cells as well as stem cell-derived cardiac cells, with
enhanced abnormal sympathetic innervation in patho-
logical conditions such as myocardial infarction or heart
transplantation due to sympathetic “nerve sprouting” as
well as disordered reinnervation [44].
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ferent pathways since biochemical networks e.g. from
the KEGG database are usually not disjoint. While no
gene was located in all three pathways we detected 4
genes common between “axon guidance” and “calcium
signaling” (PPP3R1, CHP2, PPP3CA, PPP3CC), 6 genes
in common between “calcium signaling” and “focal ad-
hesion” (PRKCB, PDGFRA, PRKCA, MYLK4, MYLK,
EGFR) as well as 11 genes in common between “axon
guidance” and “focal adhesion” (PAK1, GSK3B, PAK6,
ITGB1, PAK7, FYN, CDC42, ROCK1, ROCK2, MAPK1,
PTK2), representing likely key-players for DCM. After
removing overlapping genes respectively and repeating
the same analysis, the pathways did not remain signifi-
cant, demonstrating that these genes are of central im-
portance for the pathogenesis of DCM in these three
pathways. To further explore the role of these pathways
we removed all genes from the respective networks and
repeated the analysis. The results demonstrated a substan-
tial shift with much less significant results. The only cat-
egory which remained significant in this analysis and was
also significant in the original results and all permutation
test approaches, was “Graft-versus-host disease”. These re-
sults imply that not only the overlapping genes but also all
genes on the respective paths and, thus, the pathways
themselves play a crucial role in pathogenesis of DCM.
Permutation tests help to filter paths, which are strongly
significant in standard analyses such as the Hypergeo-
metric test, improving the specificity of network analyses.
Remarkably, already the fourth most significant pathway
in our original analysis, “neuroactive ligand-receptor inter-
action” with as many as 124 genes located within this net-
work and being highly significant (p-value of 9*10−6) was
ruled out by both permutation test strategies, where 3,564
permutations of case–control status and 7,510 permuta-
tions of original association p-values showed higher sig-
nificance than the originally calculated 9*10−6.
It is noteworthy that the permutation test strategies
led to significant results in 11 cases while the originally
applied ORA analysis did not reveal a significant result.
Some of the 11 paths showed still low p-values in the
range of 0.05 to 0.1. Nevertheless, few of these 11 path-
ways are related to heart failure at all. Genes on the T
cell receptor signaling pathway for example have shown
to categorize heart failure patients into three risk groups
[45]. The fact that the majority of these pathways is not
related to dilated cardiomyopathies further supports our
hypothesis that the consideration of Hypergeometric test
along with both permutation test strategies lead to the
most reasonable results from a biological perspective.
We repeated the most promising analysis strategy with
UC as second disease. After applying column-based per-
mutations we found a set of pathways, which was very
different from the DCM networks. Interestingly, wediscovered “Intestinal immune network for IgA produc-
tion” as most significant pathway. Immunoglobulin A
(IgA) is an antibody that plays a critical role in mucosal
immunity. More IgA is produced in mucosal linings than
all other types of antibody combined [46]. In its
secretory form, IgA is the main immunoglobulin found
in secretions from the gastrointestinal tract. Secretory
IgA protects the immunoglobulin from being degraded
by proteolytic enzymes, thus IgA can survive in the
harsh gastrointestinal tract environment and provide
protection against microbes that multiply in body secre-
tions. In the gut, IgA can bind to the mucus layer on top
of the epithelial cells to form a barrier capable of neutral-
izing threats before they reach the cell. Therefore, de-
creased or absent IgA, termed selective IgA deficiency, is a
clinically significant immunodeficiency. Recent genetic
studies have shown that a subgroup of patients with muta-
tions in known immunodeficiency genes has severe early
onset colitis. Ongoing projects now systematically screen
all known Immunodeficiency genes in early onset UC pa-
tients for mutations. It is further known that UC patients
have a dysregulated gut microbiome, i.e. especially the
bacterial diversity is reduced in UC patients. Given the im-
portance of IgA in maintaining intestinal homeostasis [47]
and in host-microbe interactions [48], an important role
of the IgA pathway in UC disease etiology is likely. All sig-
nificant genes on the core networks for UC as well as
DCM are summarized in Additional file 9: Table S4.
Although our results already revealed interesting bio-
logical results, future approaches that integrate the top-
ology of networks rather than sets of genes will enhance
the discovery of sub-networks or specific pathways that
are significantly perturbed in a certain trait.
It has to be mentioned that the three tested permutation
test approaches evaluate different null hypothesis. Particu-
larly, it should be noted that permuting SNPs explicitly
does not maintain the LD scattering any single, linked effect
among genes and potentially introducing inflation in the
null distribution. This effect may become even more im-
portant depending on how significant genes are calculated
from a list of significant SNPs. Thus, the results of the SNP
permutations have to be carefully evaluated and, where
possible, case–control permutations should be carried out.
Conclusions
Our study elucidates that for GWAS permutation of
case–control status as well as permutation of the ori-
ginal associations’ p-values are reasonable in order to
systematically uncover potential pathogenic pathways for
human diseases. Especially in the latter case, results re-
quire careful interpretation since this kind of permuta-
tion test does not maintain the LD. While the gold
standard of permuting case–control status should be
carried out, permuting SNPs appears to represent a
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are not possible. The most specific results are obtained for
those pathways, where all three approaches yielded signifi-
cant results. Furthermore we demonstrate that few thou-
sand permutations are sufficient in order to obtain reliable
results for our data example. In summary, the following
parameters for the GWAS pathway analysis showed rea-
sonable performance in our analysis: significance thresh-
old for SNPs – 0.05; permutation approach – case–
control permutations; number of permutations – 2000;
significance threshold for pathways – 0.05. Further ana-
lyses on other traits will show whether these parameters
can be generalized or have to be adapted for other GWAS
studies.
Methods
The GWAS dataset for pathway analyses: data used for
pathway analyses was retrieved from Meder et al. [49]
Stage 1 (screening phase) of this GWAS on DCM con-
sisted of 909 individuals of European descent with DCM
recruited between 2005 to 2008 and 2,120 controls from
the PopGen and KORA population-based cohorts. Case–
control association tests were conducted assuming an
underlying additive genetic model with 1 degree of free-
dom (df) using the PLINK software package version 1.07
(http://pngu.mgh.harvard.edu/purcell/plink). SNPs exhi-
biting minor allele frequencies <3%, call rates ≤95%, or de-
viations from Hardy-Weinberg equilibrium considering a
significance level of 0.05 for controls and 0.001 for cases
were excluded from further analyses. Analyses were ad-
justed for sex and age of the included unmatched individ-
uals by means of logistic regression. The genomic
inflation factor was calculated as median of all SNPs di-
vided by the median of a chi square distribution with 1 de-
gree of freedom and was used to correct p-values of the
association analyses for genomic control (GC) in order to
effectively adjust for population stratification [50].
The second GWAS data set on Ulcerative Colitis was
extracted from Ellinghaus et al. [51], consisting of 987
UC cases and 2968 healthy controls from the PopGen
and KORA cohorts. All probands are of German descent
and were genotyped using the Affymetrix Genome-Wide
Human SNP Array 6.0 plattform (Affymetrix, Santa
Clara, CA). SNPs with a minor allele frequency < 1%, call
rates ≤ 95% or significant deviation from HWE in con-
trols (p < 10−4) were excluded from further analysis. As
for the DCM data set, case–control association tests
were conducted using the PLINK software package ver-
sion 1.07 assuming an underlying additive genetic model
with 1 degree of freedom. The analysis was adjusted for
Genomic Control by using logistic regression.
Permutation tests: In order to validate the significance
of results from pathway analyses, re-sampling approaches
are commonly applied. In our study we carried out apermutation of the case–control status (permutation of
columns) as well as randomly shuffling the significance
value for each SNP (permutation of rows). First, the case–
control status has been randomly shuffled 20,000 times
and the respective runs have been evaluated according to
the methodology described earlier (in the following de-
noted as column permutations). In order to permute the
original associations’ p-values of the GWAS data analysis
as described above, original significance values have been
randomly assigned to arbitrary SNPs (in the following de-
noted as row permutations I). The latter procedure en-
sured that the total number of significant SNPs did not
vary between the various permutation test runs. Please
note that the number of significant genes nevertheless var-
ies between different permutation test runs. Additionally,
we tested a third permutation variant by randomly per-
muting the gene labels instead of the significance values of
SNPs (row permutations II). In this case, the LD is main-
tained and the sizes of random gene sets correspond to
the original size of gene sets.
Remarkably the number of possible permutations be-
tween those approaches is substantially different. Con-
sidering a GWAS with x cases and y controls and
covering z SNPs (or g Genes), a total of
xþ y
y
 
¼ xþ yð Þ!
x! y!
different permutations of case–control status are possible
while up to z! (or g!) permutations of SNP significance
values (or genes) can be carried out. Notably, for usual
GWAS the number of SNPs is considerably higher than
the number of screened individuals (z > > x + y) such that
significantly more row permutations are possible.
In order to calculate a p-value for a pathway R based
on permutation tests (either row or column permuta-
tions) we applied the following approach:
pRperm ¼
XNtot
n¼1
I pRn ≥ p
R
original
 
Ntot
Here, pRn represents the p-value for pathway R in the
n-th permutation test, pRoriginal represents the original
p-value for that pathway as calculated by the Hypergeo-
metric distribution, Ntot equals the number of permuta-
tions carried out (20,000) and I() is the indicator
function, evaluating to 0 or 1, depending whether the
permutation test is less significant as compared to the
original p-value. In order to avoid significance values of
zero in case that no permutation test is more significant
than the original data a pseudo-count can be added.
Pathway analysis: A total of 60,001 different analysis
runs have been carried out, three times 20,000 permuta-
tion tests for each column and row permutations along
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ried out with the freely available gene set analysis tool
GeneTrail [25]. As biological category 241 different KEGG
[17] pathways were considered such that altogether
around 10 million analyses were performed. To assess the
significance the Hypergeometric test was calculated. Given
a total of g significant genes of which k belong to pathway
R and a total of h genes of which i belong to R, the
p-value for enriched pathways is calculated as
Xg
j¼k
i
j
 
h‐i
g‐j
 
h
g
 
and accordingly for depleted pathways as
Xk
j¼0
i
j
 
h‐i
g‐j
 
h
g
 
After all significance values were calculated, p-values
were adjusted for multiple testing using the Benjamini
Hochberg approach [27]. All pathways with less than
two genes located onto that pathway were excluded from
significance value calculation. Besides KEGG pathways,
GeneTrail potentially offers to carry out calculation for a
substantially larger set of ten thousands of functional
biological categories including e.g. Gene Ontology [52],
chromosomal position, targets of certain miRNAs, tran-
scription factors from TRANSFAC [53] but also many
others.
Additional files
Additional file 1: Overview of the significance values resulting from
the four sets of pathway analysis as bar chart.
Additional file 2: All significance values for all pathways and all
permutation tests for the DCM dataset.
Additional file 3: Spider diagram of 26 pathways that have been
excluded by both permutation approaches, being significant just in
the original data set results.
Additional file 4: All significance values for enriched and depleted
KEGG pathways.
Additional file 5: Comparison of the average and standard
deviation for all pathways with 1,000 (black), 2,000 (blue) and 5,000
(green) permutation tests for row and column permutations
separately (DCM dataset).
Additional file 6: All significance values for the KEGG pathways for
the UC dataset.
Additional file 7: Comparison of the average and standard
deviation for all pathways with 1,000 (black), 2,000 (blue) and 5,000
(green) permutation tests for row and column permutations
separately (UC dataset).
Additional file 8: Overview of the convergence of p-values with
increasing permutation test number for the pathway “RNA polymerase”
in the UC dataset.Additional file 9: All significant genes on the core networks for UC
as well as DCM.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CB carried out permutation tests and pathway analysis, FR did the primary
data analysis of GWAS arrays, MS supported the primary data analysis of
GWAS arrays, contributed in writing the manuscript, JH and KF participated
in the analysis of the GWAS data, AF contributed in writing the manuscript
and supported the data interpretation, WL, HEW, TW, and WK participated in
the analysis of the GWAS data, HPL contributed in interpreting the data, EM
contributed in writing the manuscript and in pathway analysis, HK contributed
in study design, BM contributed in study design, data analysis and wrote the
manuscript, AK contributed in data analysis and wrote the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
The work of AK, TW, BM, HK is supported by the European Union FP7
(BestAgeing). BM and HK are grateful for support from the German Center
for Cardiovascular Research (DZHK).
Author details
1Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany.
2Department of Genetic Epidemiology, University Münster, Münster,
Germany. 3Department of Internal Medicine III, University Hospital Heidelberg,
Heidelberg, Germany. 4Institute of Clinical Molecular Biology,
Christian-Albrechts-University of Kiel, Kiel, Germany. 5German Center for
Cardiovascular Research (DZHK), Heidelberg, Germany. 6Institute of
Epidemiology and Biobank popgen, Christian-Albrechts-University Kiel, Kiel,
Germany. 7Helmholtz Center Munich, Institute of Epidemiology I, Munich,
Germany. 8Institute of Medical Informatics, Biometry and Epidemiology, Chair of
Epidemiology, Ludwig Maximilians University, Munich, Germany. 9Chair for
Bioinformatics, Saarland University, Saarbrücken, Germany. 10Department of
Human Genetics, Saarland University, Saarbrücken, Germany. 11Klaus Tschira
Institute for Integrative Computational Cardiology, Heidelberg, Germany.
Received: 10 March 2014 Accepted: 17 July 2014
Published: 22 July 2014
References
1. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK,
SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable
C, Hoh J: Complement factor H polymorphism in age-related macular
degeneration. Science 2005, 308(5720):385–389.
2. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL,
Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel
EA, Pericak-Vance MA: Complement factor H variant increases the risk of
age-related macular degeneration. Science 2005, 308(5720):419–421.
3. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS,
Manolio TA: Potential etiologic and functional implications of genome-
wide association loci for human diseases and traits. Proc Natl Acad Sci
U S A 2009, 106(23):9362–9367.
4. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki
M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW,
Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS,
Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O,
Johnson T, Li X, Guo X, Li M, Shin Cho Y, Jin Go M, Jin Kim Y: Biological,
clinical and population relevance of 95 loci for blood lipids. Nature 2010,
466(7307):707–713.
5. Holmans P, Green EK, Pahwa JS, Ferreira MA, Purcell SM, Sklar P, Owen MJ,
O’Donovan MC, Craddock N: Gene ontology analysis of GWA study data
sets provides insights into the biology of bipolar disorder. Am J Hum
Genet 2009, 85(1):13–24.
6. Khatri P, Sirota M, Butte AJ: Ten years of pathway analysis: current
approaches and outstanding challenges. PLoS Comput Biol 2012,
8(2):e1002375.
7. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set
Backes et al. BMC Genomics 2014, 15:622 Page 14 of 15
http://www.biomedcentral.com/1471-2164/15/622enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci U S A 2005,
102(43):15545–15550.
8. Keller A, Backes C, Lenhof HP: Computation of significance scores of
unweighted Gene Set Enrichment Analyses. BMC Bioinformatics 2007, 8:290.
9. Wang K, Li M, Bucan M: Pathway-based approaches for analysis of
genomewide association studies. Am J Hum Genet 2007, 81(6):1278–1283.
10. da Huang W, Sherman BT, Lempicki RA: Bioinformatics enrichment tools:
paths toward the comprehensive functional analysis of large gene lists.
Nucleic Acids Res 2009, 37(1):1–13.
11. Keller A, Backes C, Gerasch A, Kaufmann M, Kohlbacher O, Meese E, Lenhof
HP: A novel algorithm for detecting differentially regulated paths based
on gene set enrichment analysis. Bioinformatics 2009, 25(21):2787–2794.
12. Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, Georgescu C,
Romero R: A systems biology approach for pathway level analysis.
Genome Res 2007, 17(10):1537–1545.
13. Shojaie A, Michailidis G: Analysis of gene sets based on the underlying
regulatory network. J Comput Biol 2009, 16(3):407–426.
14. Rahnenfuhrer J, Domingues FS, Maydt J, Lengauer T: Calculating the
statistical significance of changes in pathway activity from gene
expression data. Stat Appl Genet Mol Biol 2004, 3:Article16.
15. Backes C, Rurainski A, Klau GW, Muller O, Stockel D, Gerasch A, Kuntzer J,
Maisel D, Ludwig N, Hein M, Keller A, Burtscher H, Kaufmann M, Meese E,
Lenhof HP, Keller A, Burtscher H, Kaufmann M, Meese E, Lenhof HP: An
integer linear programming approach for finding deregulated subgraphs
in regulatory networks. Nucleic Acids Res 2012, 40(6):e43.
16. Stockel D, Muller O, Kehl T, Gerasch A, Backes C, Rurainski A, Keller A, Kaufmann
M, Lenhof HP: NetworkTrail–a web service for identifying and visualizing
deregulated subnetworks. Bioinformatics 2013, 29(13):1702–1703.
17. Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes.
Nucleic Acids Res 2000, 28(1):27–30.
18. Karp PD, Riley M, Paley SM, Pellegrini-Toole A: The MetaCyc Database.
Nucleic Acids Res 2002, 30(1):59–61.
19. Joshi-Tope G, Vastrik I, Gopinath GR, Matthews L, Schmidt E, Gillespie M,
D’Eustachio P, Jassal B, Lewis S, Wu G, Birney E, Stein L, Birney E, Stein L:
The Genome Knowledgebase: a resource for biologists and
bioinformaticists. Cold Spring Harb Symp Quant Biol 2003, 68:237–243.
20. Braun R, Buetow K: Pathways of distinction analysis: a new technique for
multi-SNP analysis of GWAS data. PLoS Genet 2011, 7(6):e1002101.
21. Saccone SF, Bolze R, Thomas P, Quan J, Mehta G, Deelman E, Tischfield JA,
Rice JP: SPOT: a web-based tool for using biological databases to
prioritize SNPs after a genome-wide association study. Nucleic Acids Res
2010, 38(Web Server issue):W201–209.
22. Gui H, Li M, Sham PC, Cherny SS: Comparisons of seven algorithms for
pathway analysis using the WTCCC Crohn’s Disease dataset. BMC research
notes 2011, 4:386.
23. Liu G, Jiang Y, Wang P, Feng R, Jiang N, Chen X, Song H, Chen Z: Cell
adhesion molecules contribute to Alzheimer’s disease: multiple pathway
analyses of two genome-wide association studies. J Neurochem 2012,
120(1):190–198.
24. Wang K, Li M, Hakonarson H: Analysing biological pathways in genome-wide
association studies. Nat Rev Genet 2010, 11(12):843–854.
25. Backes C, Keller A, Kuentzer J, Kneissl B, Comtesse N, Elnakady YA, Muller R,
Meese E, Lenhof HP: GeneTrail–advanced gene set enrichment analysis.
Nucleic Acids Res 2007, 35(Web Server issue):W186–192.
26. Keller A, Backes C, Al-Awadhi M, Gerasch A, Kuntzer J, Kohlbacher O,
Kaufmann M, Lenhof HP: GeneTrailExpress: a web-based pipeline for the
statistical evaluation of microarray experiments. BMC bioinformatics 2008,
9:552.
27. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J R Stat Soc Ser B Methodol
1995, 57(1):289–300.
28. Wei P, Tang H, Li D: Insights into pancreatic cancer etiology from pathway
analysis of genome-wide association study data. PLoS One 2012, 7(10):e46887.
29. Liu Y, Maxwell S, Feng T, Zhu X, Elston RC, Koyuturk M, Chance MR: Gene,
pathway and network frameworks to identify epistatic interactions of
single nucleotide polymorphisms derived from GWAS data. BMC Syst Biol
2012, 6(Suppl 3):S15.
30. Zhang TX, Beaty TH, Ruczinski I: Candidate pathway based analysis for
cleft lip with or without cleft palate. Stat Appl Genet Mol Biol 2012,
11(2):1–19.31. Knijnenburg TA, Wessels LF, Reinders MJ, Shmulevich I: Fewer
permutations, more accurate P-values. Bioinformatics 2009, 25(12):i161–168.
32. Efron B, Tibshirani R: On testing the significance of sets of genes. Annals
of Applied Statistics 2007, 1(1):107–129.
33. Kresh JY, Chopra A: Intercellular and extracellular mechanotransduction
in cardiac myocytes. Pflugers Archiv: European journal of physiology 2011,
462(1):75–87.
34. Bendig G, Grimmler M, Huttner IG, Wessels G, Dahme T, Just S, Trano N,
Katus HA, Fishman MC, Rottbauer W: Integrin-linked kinase, a novel
component of the cardiac mechanical stretch sensor, controls
contractility in the zebrafish heart. Genes Dev 2006, 20(17):2361–2372.
35. Meder B, Huttner IG, Sedaghat-Hamedani F, Just S, Dahme T, Frese KS, Vogel B,
Kohler D, Kloos W, Rudloff J, Marquart S, Katus HA, Rottbauer W, Marquart S,
Katus HA, Rottbauer W: PINCH proteins regulate cardiac contractility by
modulating integrin-linked kinase-protein kinase B signaling. Mol Cell Biol
2011, 31(16):3424–3435.
36. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D: Thymosin
beta4 activates integrin-linked kinase and promotes cardiac cell
migration, survival and cardiac repair. Nature 2004, 432(7016):466–472.
37. Manso AM, Kang SM, Ross RS: Integrins, focal adhesions, and cardiac
fibroblasts. J Investig Med 2009, 57(8):856–860.
38. Ferguson DW, Berg WJ, Sanders JS: Clinical and hemodynamic correlates
of sympathetic nerve activity in normal humans and patients with heart
failure: evidence from direct microneurographic recordings. J Am Coll
Cardiol 1990, 16(5):1125–1134.
39. Floras JS: Sympathetic nervous system activation in human heart failure:
clinical implications of an updated model. J Am Coll Cardiol 2009,
54(5):375–385.
40. Fish JE, Wythe JD, Xiao T, Bruneau BG, Stainier DY, Srivastava D, Woo S: A
Slit/miR-218/Robo regulatory loop is required during heart tube
formation in zebrafish. Development 2011, 138(7):1409–1419.
41. Medioni C, Bertrand N, Mesbah K, Hudry B, Dupays L, Wolstein O,
Washkowitz AJ, Papaioannou VE, Mohun TJ, Harvey RP, Zaffran S, Zaffran S:
Expression of Slit and Robo genes in the developing mouse heart.
Dev Dyn 2010, 239(12):3303–3311.
42. Damon DH: Vascular endothelial-derived semaphorin 3 inhibits
sympathetic axon growth. Am J Physiol Heart Circ Physiol 2006,
290(3):H1220–1225.
43. Mommersteeg MT, Andrews WD, Ypsilanti AR, Zelina P, Yeh ML, Norden J,
Kispert A, Chedotal A, Christoffels VM, Parnavelas JG: Slit-roundabout
signaling regulates the development of the cardiac systemic venous
return and pericardium. Circ Res 2013, 112(3):465–475.
44. Miwa K, Lee JK, Takagishi Y, Opthof T, Fu X, Hirabayashi M, Watabe K,
Jimbo Y, Kodama I, Komuro I: Axon guidance of sympathetic neurons to
cardiomyocytes by glial cell line-derived neurotrophic factor (GDNF).
PLoS One 2013, 8(7):e65202.
45. Vanburen P, Ma J, Chao S, Mueller E, Schneider DJ, Liew CC: Blood gene
expression signatures associate with heart failure outcomes. Physiol
Genomics 2011, 43(8):392–397.
46. Fagarasan S, Honjo T: Intestinal IgA synthesis: regulation of front-line
body defences. Nat Rev Immunol 2003, 3(1):63–72.
47. Brandtzaeg P: Secretory IgA: designed for anti-microbial defense. Frontiers
in immunology 2013, 4:222.
48. Kelly D, Mulder IE: Microbiome and immunological interactions. Nutr Rev
2012, 70(Suppl 1):S18–30.
49. Meder B, Ruhle F, Weis T, Homuth G, Keller A, Franke J, Peil B, Lorenzo Bermejo
J, Frese K, Huge A, Witten A, Vogel B, Haas J, Volker U, Ernst F, Teumer A,
Ehlermann P, Zugck C, Friedrichs F, Kroemer H, Dorr M, Hoffmann W, Maisch B,
Pankuweit S, Ruppert V, Scheffold T, Kuhl U, Schultheiss HP, Kreutz R, Ertl G: A
genome-wide association study identifies 6p21 as novel risk locus for
dilated cardiomyopathy. Eur Heart J 2014, 35(16):1069–1077.
50. Devlin B, Roeder K: Genomic control for association studies. Biometrics
1999, 55(4):997–1004.
51. Ellinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T,
Laerdahl JK, Shiryaev A, Gotthardt DN, Weismuller TJ, Schramm C, Wittig M,
Bergquist A, Bjornsson E, Marschall HU, Vatn M, Teufel A, Rust C, Gieger C,
Wichmann HE, Runz H, Sterneck M, Rupp C, Braun F, Weersma RK,
Wijmenga C, Ponsioen CY, Mathew CG, Rutgeerts P, Vermeire S:
Genome-wide association analysis in primary sclerosing cholangitis and
ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology 2013,
58(3):1074–1083.
Backes et al. BMC Genomics 2014, 15:622 Page 15 of 15
http://www.biomedcentral.com/1471-2164/15/62252. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP,
Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A,
Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G:
Gene ontology: tool for the unification of biology. The Gene Ontology
Consortium. Nat Genet 2000, 25(1):25–29.
53. Wingender E, Chen X, Hehl R, Karas H, Liebich I, Matys V, Meinhardt T,
Pruss M, Reuter I, Schacherer F: TRANSFAC: an integrated system for gene
expression regulation. Nucleic Acids Res 2000, 28(1):316–319.
doi:10.1186/1471-2164-15-622
Cite this article as: Backes et al.: Systematic permutation testing in
GWAS pathway analyses: identification of genetic networks in dilated
cardiomyopathy and ulcerative colitis. BMC Genomics 2014 15:622.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
